Cita APA (7th ed.)

Nyman, H., Jerkeman, M., Karjalainen-Lindsberg, M., Banham, A., Enblad, G., & Leppa, S. (2008). BCL-2 but not FOXP1, is an adverse risk factor in immunochemotherapy treated non-germinal center diffuse large B-cell lymphomas.

Cita Chicago (17th ed.)

Nyman, H., M. Jerkeman, M. Karjalainen-Lindsberg, A. Banham, G. Enblad, i S. Leppa. BCL-2 but Not FOXP1, Is an Adverse Risk Factor in Immunochemotherapy Treated Non-germinal Center Diffuse Large B-cell Lymphomas. 2008.

Cita MLA (9th ed.)

Nyman, H., et al. BCL-2 but Not FOXP1, Is an Adverse Risk Factor in Immunochemotherapy Treated Non-germinal Center Diffuse Large B-cell Lymphomas. 2008.